- Home
- STOK vs CTO Comparison
STOK vs CTO Comparison
Compare STOK & CTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STOK
- CTO
- Stock Information
- Founded
- STOK 2014
- CTO 1902
- Country
- STOK United States
- CTO United States
- Employees
- STOK N/A
- CTO N/A
- Industry
- STOK Biotechnology: Pharmaceutical Preparations
- CTO Real Estate Investment Trusts
- Sector
- STOK Health Care
- CTO Real Estate
- Exchange
- STOK Nasdaq
- CTO Nasdaq
- Market Cap
- STOK 638.8M
- CTO 568.5M
- IPO Year
- STOK 2019
- CTO N/A
- Fundamental
- Price
- STOK $12.03
- CTO $17.31
- Analyst Decision
- STOK Strong Buy
- CTO Strong Buy
- Analyst Count
- STOK 5
- CTO 3
- Target Price
- STOK $24.50
- CTO $22.33
- AVG Volume (30 Days)
- STOK 541.2K
- CTO 384.2K
- Earning Date
- STOK 08-06-2025
- CTO 07-29-2025
- Dividend Yield
- STOK N/A
- CTO 8.79%
- EPS Growth
- STOK N/A
- CTO N/A
- EPS
- STOK 0.88
- CTO N/A
- Revenue
- STOK $190,908,000.00
- CTO $132,203,000.00
- Revenue This Year
- STOK $378.84
- CTO $20.11
- Revenue Next Year
- STOK N/A
- CTO $8.51
- P/E Ratio
- STOK $13.80
- CTO N/A
- Revenue Growth
- STOK 2333.81
- CTO 17.48
- 52 Week Low
- STOK $5.35
- CTO $16.12
- 52 Week High
- STOK $16.15
- CTO $21.15
- Technical
- Relative Strength Index (RSI)
- STOK 67.00
- CTO 41.67
- Support Level
- STOK $11.19
- CTO $17.15
- Resistance Level
- STOK $12.00
- CTO $17.73
- Average True Range (ATR)
- STOK 0.54
- CTO 0.34
- MACD
- STOK -0.04
- CTO -0.04
- Stochastic Oscillator
- STOK 75.30
- CTO 37.10
About STOK Stoke Therapeutics Inc.
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.
About CTO CTO Realty Growth Inc.
CTO Realty Growth Inc is a real estate investment trust company, that owns income properties comprised of approximately 2.7 million square feet in diversified markets in the United States. Its portfolio of assets consists of Income Properties Portfolio, management services, Commercial Loan and Investments.